CTOs on the Move

TSN Labs Inc

www.tsn2000.com

 
TSN Labs Inc is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tsn2000.com
  • 6146 S 350 W
    Salt Lake City, UT USA 84107
  • Phone: 801.261.2252

Executives

Name Title Contact Details

Similar Companies

CompManagement Health Systems

CompManagement Health Systems, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Providers Of Minnesota

Care Providers Of Minnesota is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apollo Medical

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Little River Healthcare System

Little River Healthcare System is a Rockdale, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.